59.01
price down icon1.26%   -0.75
after-market Dopo l'orario di chiusura: 59.01
loading
Precedente Chiudi:
$59.76
Aprire:
$60.06
Volume 24 ore:
1.24M
Relative Volume:
0.61
Capitalizzazione di mercato:
$11.32B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
21.94
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
+3.00%
1M Prestazione:
+9.00%
6M Prestazione:
-4.41%
1 anno Prestazione:
-31.06%
Intervallo 1D:
Value
$58.87
$60.09
Intervallo di 1 settimana:
Value
$56.48
$60.29
Portata 52W:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
Nome
Biomarin Pharmaceutical Inc
Name
Telefono
(415) 506-6700
Name
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Name
Dipendente
3,040
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-29
Name
Ultimi documenti SEC
Name
BMRN's Discussions on Twitter

Confronta BMRN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
59.01 11.46B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-03 Ripresa Morgan Stanley Overweight
2025-02-24 Aggiornamento Oppenheimer Perform → Outperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-10-30 Downgrade William Blair Outperform → Mkt Perform
2024-10-10 Ripresa Raymond James Outperform
2024-08-20 Aggiornamento Bernstein Mkt Perform → Outperform
2024-05-17 Downgrade Robert W. Baird Outperform → Neutral
2024-05-14 Iniziato Evercore ISI Outperform
2023-11-15 Iniziato Wells Fargo Overweight
2023-10-23 Aggiornamento Bernstein Underperform → Mkt Perform
2023-09-28 Iniziato Raymond James Mkt Perform
2023-09-18 Iniziato UBS Buy
2023-07-27 Iniziato Scotiabank Sector Perform
2023-07-05 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-06-14 Ripresa Credit Suisse Outperform
2023-03-21 Iniziato Bernstein Underperform
2023-02-22 Downgrade Oppenheimer Outperform → Perform
2023-02-21 Iniziato Citigroup Neutral
2023-01-30 Iniziato BMO Capital Markets Market Perform
2023-01-18 Iniziato Canaccord Genuity Hold
2022-10-31 Aggiornamento Oppenheimer Perform → Outperform
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-13 Ripresa Wedbush Neutral
2022-04-25 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-11-22 Aggiornamento William Blair Mkt Perform → Outperform
2021-10-07 Ripresa Jefferies Buy
2021-09-09 Aggiornamento Stifel Hold → Buy
2021-06-04 Ripresa Robert W. Baird Outperform
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-04 Ripresa Guggenheim Buy
2021-03-01 Aggiornamento Evercore ISI In-line → Outperform
2020-08-20 Downgrade Citigroup Buy → Neutral
2020-08-20 Downgrade William Blair Outperform → Mkt Perform
2020-08-19 Downgrade Evercore ISI Outperform → In-line
2020-08-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-08-19 Downgrade Stifel Buy → Hold
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-07-06 Reiterato Citigroup Buy
2020-01-28 Iniziato BMO Capital Markets Market Perform
2020-01-27 Iniziato BMO Capital Markets Market Perform
2020-01-24 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2019-11-27 Aggiornamento Barclays Equal Weight → Overweight
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-05-23 Ripresa Citigroup Buy
2019-04-09 Ripresa Raymond James Outperform
2019-01-02 Downgrade Raymond James Outperform → Mkt Perform
2018-12-14 Iniziato Wolfe Research Outperform
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-08-07 Reiterato Stifel Buy
2018-08-03 Reiterato Stifel Buy
Mostra tutto

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

pulisher
03:32 AM

What analysts say about BioMarin Pharmaceutical Inc. stockOutstanding growth strategies - PrintWeekIndia

03:32 AM
pulisher
08:59 AM

Is BioMarin Pharmaceutical Inc. a good long term investmentStrongest growth potential - PrintWeekIndia

08:59 AM
pulisher
Jul 24, 2025

BioMarin’s BMN 349: A Promising Step in Genetic Lung Condition Treatment - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Published on: 2025-07-25 23:58:58 - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What risks could impact BioMarin Pharmaceutical Inc. stock performanceRapid wealth creation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Will BioMarin Pharmaceutical Inc. stock benefit from AI tech trendsFree Consultation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - Eastern Progress

Jul 24, 2025
pulisher
Jul 23, 2025

BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

BioMarin Pharmaceutical Inc. Stock Analysis and ForecastOutstanding growth strategies - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives BioMarin Pharmaceutical Inc. stock priceAccelerated earnings growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st

Jul 22, 2025
pulisher
Jul 19, 2025

BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize

Jul 19, 2025
pulisher
Jul 17, 2025

BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo

Jul 17, 2025
pulisher
Jul 16, 2025

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛

Jul 16, 2025
pulisher
Jul 16, 2025

Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research

Jul 16, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 14, 2025

What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts

Jul 14, 2025
pulisher
Jul 14, 2025

Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks - Yahoo Finance

Jul 14, 2025
pulisher
Jul 13, 2025

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com

Jul 11, 2025
pulisher
Jul 10, 2025

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey

Jul 09, 2025

Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):